Metraipolis › archive › dc_6dca5195c2bd

Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A… — Europe PMC PMID:42275400

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42275400
DOI
10.1371/journal.pone.0351029
License (as archived)
solo-consultazione
Archived
2026-10-31T14:15:37.751Z
SHA-256 of the archived text
21b697bfaeb91f7e1e11bfcb163db2c913a7ce15c78d31b189f0c419ba7df374
Stable URL of this page
https://metraipolis.com/documento/dc_6dca5195c2bd

How to cite

Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A… — Europe PMC PMID:42275400 — Europe PMC (en), https://europepmc.org/article/MED/42275400 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_6dca5195c2bd (Metraipolis archive dc_6dca5195c2bd, sha256 21b697bfaeb91f7e1e11bfcb163db2c913a7ce15c78d31b189f0c419ba7df374)
BibTeX
@misc{dc6dca5195c2bd,
  title = {Economic evaluation of atezolizumab in combination with bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer in China: A… — Europe PMC PMID:42275400},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42275400},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_6dca5195c2bd; sha256 21b697bfaeb91f7e1e11bfcb163db2c913a7ce15c78d31b189f0c419ba7df374},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42275400. Agents can read the archived copy with the MCP tool read_document.